Patents by Inventor Michael Sedlmayr

Michael Sedlmayr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline brexpiprazole
    Patent number: 11072605
    Abstract: The present invention relates to crystalline brexpiprazole having a particle size distribution (PSD) characterized by a d(90) of 30 ?m to 100 ?m, by a d(10) of at least 1.0 ?m, and by a d(4,3) of at least 15.0 ?m. The present invention also relates to a pharmaceutical composition comprising a crystalline brexpiprazole having a PSD characterized by a d(90) of 30 ?m to 100 ?m, by a d(10) of at least 1.0 ?m, and by a d(4,3) of at least 15.0 ?m, and to an aqueous suspension comprising said crystalline brexpiprazole. The present invention also relates to a composition comprising a crystalline brexpiprazole having a PSD characterized by a d(90) of 30 ?m to 100 ?m, by a d(10) of at least 1.0 ?m, and by a d(4,3) of at least 15.0 ?m, wherein said composition is essentially free from secondary particles of brexpiprazole.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: July 27, 2021
    Assignee: Hexal AG
    Inventors: Andreas Krekeler, Michael Sedlmayr
  • Crystalline Brexpiprazole
    Publication number: 20190389847
    Abstract: The present invention relates to crystalline brexpiprazole having a particle size distribution (PSD) characterized by a d(90) of 30 ?m to 100 ?m, by a d(10) of at least 1.0 ?m, and by a d(4,3) of at least 15.0 ?m. The present invention also relates to a pharmaceutical composition comprising a crystalline brexpiprazole having a PSD characterized by a d(90) of 30 ?m to 100 ?m, by a d(10) of at least 1.0 ?m, and by a d(4,3) of at least 15.0 ?m, and to an aqueous suspension comprising said crystalline brexpiprazole. The present invention also relates to a composition comprising a crystalline brexpiprazole having a PSD characterized by a d(90) of 30 ?m to 100 ?m, by a d(10) of at least 1.0 ?m, and by a d(4,3) of at least 15.0 ?m, wherein said composition is essentially free from secondary particles of brexpiprazole.
    Type: Application
    Filed: February 1, 2018
    Publication date: December 26, 2019
    Applicant: Hexal Aktiengesellschaft
    Inventors: Andreas Krekeler, Michael Sedlmayr
  • Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix
    Patent number: 10485799
    Abstract: The present invention relates to a solid oral pharmaceutical composition comprising vortioxetine hydrobromide in a matrix formed from at least one polyethylene oxide and optionally one or more further matrix forming polymers.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: November 26, 2019
    Assignee: Hexal AG
    Inventors: Andreas Krekeler, Dimitri Neumann, Michael Sedlmayr
  • Solid dispersion comprising an orexin receptor antagonist
    Patent number: 10206880
    Abstract: A solid dispersion comprising suvorexant or a salt thereof in amorphous form and at least one pharmaceutically acceptable matrix compound, wherein the matrix compound is (i) a polymer and wherein the solid dispersion contains the suvorexant or salt thereof in an 5 amount of at least 50 weight-% based on the combined weight of the suvorexant or salt thereof and the at least one matrix compound, or (ii) a silicon-based inorganic adsorbent.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: February 19, 2019
    Assignee: Sandoz AG
    Inventors: Verena Adamer, Andreas Krekeler, Michael Sedlmayr
  • Pharmaceutical Composition Of Vortioxetine Hydrobromide Comprising Vortioxetine Hydrobromide In A Polyethylene Oxide Matrix
    Publication number: 20170182034
    Abstract: The present invention relates to a solid oral pharmaceutical composition comprising vortioxetine hydrobromide in a matrix formed from at least one polyethylene oxide and optionally one or more further matrix forming polymers.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 29, 2017
    Applicant: Hexal AG
    Inventors: Andreas Krekeler, Dimitri Neumann, Michael Sedlmayr
  • Solid Dispersion Comprising An Orexin Receptor Antagonist
    Publication number: 20170027873
    Abstract: A solid dispersion comprising suvorexant or a salt thereof in amorphous form and at least one pharmaceutically acceptable matrix compound, wherein the matrix compound is (i) a polymer and wherein the solid dispersion contains the suvorexant or salt thereof in an 5 amount of at least 50 weight-% based on the combined weight of the suvorexant or salt thereof and the at least one matrix compound, or (ii) a silicon-based inorganic adsorbent.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 2, 2017
    Applicant: Sandoz AG
    Inventors: Verena Adamer, Andreas Krekeler, Michael Sedlmayr
  • TABLET WITH INCREASED DRUG LOAD OF ODANACATIB
    Publication number: 20160106679
    Abstract: The present invention relates to pharmaceutical tablets comprising amorphous compound I in the form of its free base or pharmaceutically acceptable salts of compound I.
    Type: Application
    Filed: May 16, 2014
    Publication date: April 21, 2016
    Inventors: Johannes Raneburger, Ludwig Englmeier, Andreas Krekeler, Michael Sedlmayr
  • TABLET WITH INCREASED DRUG LOAD OF ODANACATIB
    Publication number: 20160081937
    Abstract: The present invention relates to pharmaceutical tablets comprising amorphous compound I or pharmaceutically acceptable salts thereof, and an inert organic carrier.
    Type: Application
    Filed: May 16, 2014
    Publication date: March 24, 2016
    Inventors: Johannes Raneburger, Ludwig Englmeier, Andreas Krekeler, Michael Sedlmayr